Pharma BD Deal Intelligence
UCB's up-to-$1.9B buyout of Zogenix cashed in its own CVR: Fintepla won FDA approval for Lennox-Gastaut syndrome just three weeks after the March 2022 close and EU approval followed in February 2023, and the drug has since scaled past 14,000 rare-epilepsy patients.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →UCB will pay up to $1.9 billion to acquire Zogenix, a U.S. biotech that markets the rare epilepsy treatment Fintepla, in a deal that adds to the Belgian…
Belgium's UCB said on Wednesday it had agreed to buy Zogenix in a deal worth up to $1.9 billion to gain the U.S. drugmaker's rare epilepsy drug Fintepla and…
UCB FY2025 results: FINTEPLA reached over 14,000 patients and families living with seizures associated with rare epileptic syndromes by end-2025, and is named…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
UCB acquired Zogenix for up to ~$1.9B ($26/share cash plus a $2/share contingent value right tied to EU approval of Fintepla in Lennox-Gastaut syndrome by 31 Dec 2023). The deal added Fintepla (fenfluramine), an FDA-approved oral solution for Dravet syndrome, expanding UCB's epilepsy and rare-neurology franchise as legacy antiseizure brands (e.g. Vimpat) faced generic erosion. The deal closed 7 March 2022. The acquisition thesis has since been validated: the FDA approved Fintepla for Lennox-Gastaut syndrome on 28 March 2022 and the EU followed on 8 February 2023 — satisfying the CVR milestone ahead of the deadline, so the full ~$1.9B consideration (including the $2/share CVR) was realized. Fintepla has scaled into a UCB growth driver, reaching over 14,000 patients with rare epileptic syndromes by end-2025.
30K US cases/yr · $900M Global LGS branded therapeutics 2023 · >90% Patients pharmacoresistant to standard AEDs
Lennox-Gastaut syndrome is a severe childhood-onset epileptic encephalopathy defined by multiple seizure types (notably tonic, atonic, and atypical absence seizures), a slow spike-wave pattern on EEG, and progressive intellectual disability with a high lifetime burden of injury, hospitalization, and caregiver disruption. LGS represents 1-4% of all childhood epilepsies, with U.S. prevalence estimates of roughly 30,000-50,000 patients across pediatric and adult populations as patients age into adulthood with persistent disease, creating an unusual cross-specialty pharmacotherapy footprint. Treatment is broadly polypharmacy-driven and historically refractory: valproate, clobazam, lamotrigine, topiramate, rufinamide (Banzel) and felbamate are foundational AEDs, with newer additions Epidiolex (cannabidiol, 2018), Fintepla (fenfluramine, 2022 LGS approval), and surgical interventions including vagus nerve stimulation (VNS) and corpus callosotomy in pharmacoresistant candidates. Drop-seizure frequency is the central efficacy and safety lever — driving injury risk, ER utilization, and hospitalization burden — and pivotal trials in LGS routinely use 50%+ drop-seizure responder rate as the primary endpoint. Pediatric neurology drives prescribing through specialized epilepsy centers; adult neurology has growing exposure as patients transition through adolescence into the adult care system, creating handoff continuity and payer step-therapy pressure points.
LGS competitive dynamics are dominated by drop-seizure reduction as the central efficacy and safety endpoint, with payer review and PA frameworks built around 50%+ responder rates and reduction in injury-related hospitalization. Fintepla (fenfluramine, UCB) gained FDA approval for LGS in March 2022 on Phase 3 data showing significant reduction in monthly drop-seizure frequency versus placebo on top of background AED therapy. Epidiolex (cannabidiol, Jazz Pharmaceuticals) holds a 2018 LGS label and broad utilization across pediatric and adult LGS populations. Banzel (rufinamide, Eisai) remains an established add-on across both pediatric and adult tiers. Onfi (clobazam, Lundbeck/Catalyst Pharmaceuticals) is a foundational benzodiazepine in long-term LGS regimens. Sympazan (clobazam oral film, Aquestive) provides a differentiated dosage form for patients with swallowing difficulty. Beyond pharmacotherapy, Vagus Nerve Stimulation (LivaNova) and corpus callosotomy are surgical options for the most treatment-resistant patients. Pipeline competitors include cenobamate (Xcopri, SK Biopharm/SK Life Science) being studied in LGS, ganaxolone (Ztalmy, Marinus Pharmaceuticals) approved in adjacent CDKL5 deficiency disorder, and soticlestat (Takeda) in late-stage development for both Dravet and LGS pending Phase 3 SKYLINE/SKYWAY readouts.
21K US cases/yr · $1.1B Estimated combined Dravet/LGS branded market 2023 · ~15-20% Lifetime mortality (largely SUDEP)
Dravet syndrome is a severe, treatment-resistant developmental and epileptic encephalopathy that emerges in the first year of life, almost always linked to loss-of-function de novo mutations in the SCN1A gene encoding the Nav1.1 voltage-gated sodium channel. The condition is characterized by frequent prolonged febrile and afebrile seizures, status epilepticus risk, intellectual disability, motor decline, autonomic dysfunction, and a 15-20% lifetime mortality rate by early adulthood, much of which is from sudden unexpected death in epilepsy (SUDEP). U.S. prevalence is estimated at approximately 1 in 15,700 live births, translating to roughly 21,000-25,000 patients across pediatric and adult tiers. Standard of care has historically been valproate plus clobazam, with stiripentol added in 2018 and topiramate frequently used adjunctively; the modern era was reset by Epidiolex (cannabidiol) in 2018 and Fintepla (fenfluramine) in 2020, the latter of which delivered a step-change in seizure-frequency reduction in pivotal Phase 3 trials. Pediatric neurologists and epileptologists drive prescribing through specialized epilepsy centers and patient advocacy networks; payer coverage is generally established for the branded triplet but utilization management, prior authorization, and step therapy through Epidiolex before Fintepla are common in commercial and Medicaid plans.
The Dravet competitive arena is a three-product branded market with substantial cross-prescribing across lines and considerable polypharmacy at the patient level. Fintepla (fenfluramine, UCB/Zogenix) is a serotonin (5-HT2) and sigma-1 receptor agonist, FDA-approved 2020 for Dravet syndrome and 2022 for Lennox-Gastaut syndrome, and is the asset that drove UCB's $1.9B Zogenix acquisition; cardiac monitoring under a REMS framework is required given fenfluramine's historical fen-phen association. Epidiolex (cannabidiol, Jazz Pharmaceuticals via the GW Pharmaceuticals acquisition) is broadly used as an add-on across Dravet, LGS, and tuberous sclerosis complex, with deep payer coverage. Diacomit (stiripentol, Biocodex) is FDA-approved for adjunctive Dravet use in combination with valproate and clobazam. Emerging assets are reshaping the long-term frame: Stoke Therapeutics' zorevunersen (STK-001), an antisense oligonucleotide upregulating SCN1A expression, is in Phase 3 EMPEROR following Phase 1/2 evidence of seizure reduction and cognitive improvement signals — a potential first disease-modifying agent that could disrupt the symptomatic-control incumbents. Encoded Therapeutics' ETX101 AAV gene therapy is in early clinical development with a similar SCN1A-targeted disease-modifying ambition.
Just after deal close, the FDA approved Fintepla (fenfluramine) for seizures associated with LGS, expanding the label beyond Dravet syndrome.
The European Commission approved Fintepla for adjunctive treatment of LGS, satisfying the $2/share CVR milestone (deadline 31 Dec 2023). The full ~$1.9B consideration including the CVR was thereby realized.
By end-2025 Fintepla reached over 14,000 patients with rare epileptic syndromes and is one of UCB's named growth drivers, confirming the deal as a commercial success.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Zogenix Inc. (this deal) | 2022 | $1.9B | — |
| UCB S.A. / Candid Therapeutics, Inc. | 2026 | $2.2B | — |
| UCB S.A. / Ra Pharmaceuticals, Inc. | 2019 | $2.1B | — |
| UCB S.A. / Neurona Therapeutics, Inc. | 2026 | $1.1B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2022 deals · UCB S.A. deals · Neurology deals